During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

A U.S. Agency for International Development funding freeze in January forced the closure of India’s Mitr Clinic, the ...

Master injector Alexander Tirado, who brings unmatched passion and intimate knowledge of multiple disciplines, has been ...

At least two dozen bills have been introduced across 15 states this year. Most of the legislation is related to ...

Skin health experts debunk collagen myths, like whether or not collagen supplements really work, and all the ways you can ...

The legislation will have a major impact on health access and may disrupt who can seek out healthcare essentials, like ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...

The resolution supports members of the trans community being able to get puberty blockers, hormone replacement therapy and ...